호흡기 세포융합 바이러스(RSV) 백신 시장 기회 및 전략(-2035년)

A respiratory syncytial virus (RSV) vaccine is a biological preparation designed to stimulate the immune system to protect against RSV infection, a common respiratory virus that can cause severe illness, especially in infants, older adults, and individuals with weakened immune systems. These vaccines may use different technologies, including protein subunit, messenger ribonucleic acid (mRNA), or vector-based platforms, to trigger protective immunity. The primary purpose of an RSV vaccine is to prevent RSV-related respiratory infections, hospitalizations, and complications, particularly in high-risk populations.

The global respiratory syncytial virus vaccine market was valued at $2,548.9 million in 2023 which grew till $1,175.4 million in 2025.

Growing Rate Of Premature Birth

During the historic period, the respiratory syncytial virus vaccine market was mainly restrained by the growing rate of premature birth. Rising preterm deliveries (births before 37 completed weeks of gestation) increased the clinical complexity of pregnancy management and neonatal care, leading to greater caution around maternal immunization strategies. Moreover, sustained increases in preterm birth rates signal broader maternal and child health challenges, including higher rates of low birthweight and adverse perinatal outcomes, which can delay guideline updates and slow the integration of new vaccines into routine obstetric practice. For instance, in June 2023, the Pan American Health Organization, the specialized international public health agency for the Americas, reported that 152 million babies were born preterm over the last decade, noting that preterm birth remains the leading cause of death in children under five. The report emphasized that premature newborns face disproportionately high risks of respiratory infections and complications due to incomplete organ development. Therefore, the respiratory syncytial virus vaccine market was mainly restrained by the growing rate of premature birth.

Expansion Of RSV Vaccine Approvals To Include Younger At-Risk Adult Populations

Major companies in the respiratory syncytial virus vaccine market are focusing on expanding vaccine indications to include younger adults who are at increased risk of severe RSV disease due to underlying medical conditions. These developments aim to broaden immunization coverage beyond older adults, offering protection to individuals aged 18 to 59 who may be vulnerable because of chronic health issues such as asthma, COPD, heart disease or diabetes. For instance, in October 2024, Pfizer, a US-based multinational biopharmaceutical company specializing in vaccine development and infectious-disease therapeutics, received approval from the U.S. Food and Drug Administration (FDA) for Abrysvo for use in adults aged 18 through 59 years who are at increased risk for RSV lower respiratory tract disease. The approval was supported by data from a Phase 3 clinical trial demonstrating strong immunogenicity and safety in younger at-risk adults, marking the first time an RSV vaccine has been authorized for this demographic. By leveraging its extensive vaccine expertise and clinical research capabilities, the company aims to expand RSV protection to a broader adult population and strengthen overall community immunity across the United States.

The global respiratory syncytial virus vaccine market is highly concentrated, with large players operating in the market. The top 3 competitors in the market made up 100.0% of the total market in 2024.

Respiratory Syncytial Virus Vaccine Global Market Opportunities And Strategies To 2035 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global respiratory syncytial virus vaccine market as it emerges from the COVID-19 shut down.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market research findings.
• Benchmark performance against key competitors.
• Utilize the relationships between key data sets for superior strategizing.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.

Where is the largest and fastest-growing market for respiratory syncytial virus vaccine? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The respiratory syncytial virus vaccine market global report from The Business Research Company answers all these questions and many more.

The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market's history and forecasts market growth by geography. It places the market within the context of the wider respiratory syncytial virus vaccine market; and compares it with other markets.

The report covers the following chapters

• Introduction and Market Characteristics- Brief introduction to the segmentations covered in the market, definitions and explanations about the segment by type, by clinical indications and by distribution channel.
• Key Trends- Highlights the major trends shaping the global market. This section also highlights likely future developments in the market.
• Growth Analysis And Strategic Analysis Framework Analysis on PESTEL, end use industries, market growth rate, global historic (2020-2025) and forecast (2025-2030, 2035F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods, forecast growth contributors and total addressable market (TAM).
• Global Market Size And Growth Global historic (2020-2025) and forecast (2025-2030, 2035F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods.
• Regional And Country Analysis Historic (2020-2025) and forecast (2025-2030, 2035F) market values and growth and market share comparison by region and country.
• Market Segmentation Contains the market values (2020-2025) (2025-2030, 2035F) and analysis for each segment by type, by clinical indications and by distribution channel in the market. Historic (2020-2025) and forecast (2025-2030) and (2030-2035) market values and growth and market share comparison by region market.
• Regional Market Size And Growth Regional market size (2025), historic (2020-2025) and forecast (2025-2030, 2035F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
• Competitive Landscape- Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players
• Other Major And Innovative Companies Details on the company profiles of other major and innovative companies in the market
• Competitive Benchmarking- Briefs on the financials comparison between major players in the market.
• Competitive Dashboard- Briefs on competitive dashboard of major players.
• Key Mergers and Acquisitions- Information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions, which have shaped the market in recent years.
• Recent Developments Information on recent developments in the market covered in the report.
• Market Opportunities And Strategies- Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
• Conclusions And Recommendations- This section includes recommendations for respiratory syncytial virus vaccine providers in terms of product/service offerings geographic expansion, marketing strategies and target groups.
• Appendix- This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.

Markets Covered:

• 1) By Type: Viral Vaccine; Bacterial Vaccine; Combination Vaccine
• 2) By Clinical Indications: Pediatric Indication; Geriatric Indication; High-Risk Individuals
• 3) By Distribution Channel: Hospital And Others Pharmacies; Government Suppliers
• Companies Mentioned: GlaxoSmithKline plc; Pfizer Inc; Moderna Inc.
• Countries: China; Australia; India; Indonesia; Japan; South Korea; USA; Canada; Brazil; France; Germany; UK; Italy; Spain; Russia
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time-series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; respiratory syncytical virus vaccine indicators comparison.
• Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Table of Contents

1 Executive Summary

• 1.1 Respiratory Syncytial Virus Vaccine - Market Attractiveness And Macro Economic Landscape

2 Table Of Contents

3 List Of Tables

4 List Of Figures

5 Report Structure

6 Market Characteristics

• 6.1 General Market Definition
• 6.2 Summary
• 6.3 Respiratory Syncytial Virus Vaccine Market Definition And Segmentations
• 6.4 Market Segmentation By Type
  • 6.4.1 Viral Vaccine
  • 6.4.2 Combination Vaccine
• 6.5 Market Segmentation By Clinical Indications
  • 6.5.1 Pediatric Indication
  • 6.5.2 Geriatric Indication
  • 6.5.3 High-Risk Individuals
• 6.6 Market Segmentation By Distribution Channel
  • 6.6.1 Hospitals and Other Pharmacies
  • 6.6.2 Government Suppliers

7 Respiratory Syncytial Virus Vaccine Market Biologic Drug Characteristics

• 7.1 Molecule Type
• 7.2 Route of Administration (ROA)
• 7.3 Mechanism of Action (MOA)
• 7.4 Safety and Efficacy

8 Major Market Trends

• 8.1 Expansion Of RSV Vaccine Approvals To Include Younger At-Risk Adult Populations
• 8.2 Launch of mRNA-Based RSV Vaccines Expands Preventive Options for Adults
• 8.3 Expansion of AREXVY Indication to Adults Aged 50-59 at Risk Widens RSV Vaccine Uptake

9 Respiratory Syncytial Virus Vaccine Market - Macro Economic Scenario

10 Global Respiratory Syncytial Virus Vaccine Growth Analysis And Strategic Analysis Framework

• 10.1 Global PESTEL Analysis
  • 10.1.1 Political
  • 10.1.2 Economic
  • 10.1.3 Social
  • 10.1.4 Technological
  • 10.1.5 Environmental
  • 10.1.6 Legal
• 10.2 Analysis Of End User (B2C)
  • 10.2.1 Infants and Young Children
  • 10.2.2 Pregnant Women
  • 10.2.3 Older Adults (>60 Years)
  • 10.2.4 Immunocompromised Individuals
  • 10.2.5 Healthcare Workers and Caregivers
• 10.3 Global Respiratory Syncytial Virus Vaccine Market Growth Rate Analysis
• 10.4 Historic Market Growth, 2020 - 2025, Value ($ Million)
  • 10.4.1 Market Drivers 2020 - 2025
  • 10.4.2 Market Restraints 2020-2025
• 10.5 Forecast Market Growth, 2025 - 2030, 2035F Value ($ Million)
  • 10.5.1 Market Drivers 2025 - 2030
  • 10.5.2 Market Restraints 2025 - 2030
• 10.6 Total Addressable Market for the Respiratory Syncytial Virus Vaccine Market - Business to Customer (B2C)
  • 10.6.1 TAM Comparison Analysis

11 Global Respiratory Syncytial Virus Vaccine Pricing Analysis & Forecasts

12 Respiratory Syncytial Virus Monoclonal Antibodies Pipeline Analysis

13 Qualitative Insights Regarding Vaccination For Pregnant Women (Covering Pfizer's Abrisvo (Abrysvo))

14 Global Respiratory Syncytial Virus Vaccine Market Segmentation

• 14.1 Global Respiratory Syncytial Virus Vaccine Market, Segmentation By Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 14.2 Global Respiratory Syncytial Virus Vaccine Market, Segmentation By Clinical Indications, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 14.3 Global Respiratory Syncytial Virus Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)

15 Respiratory Syncytial Virus Vaccine Market, Regional and Country Analysis

• 15.1 Global Respiratory Syncytial Virus Vaccine Market, By Region, Historic and Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 15.2 Global Respiratory Syncytial Virus Vaccine Market, By Country, Historic and Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)

16 Global Respiratory Syncytial Virus Vaccine Epidemiology Of Clinical Indications

• 16.1 Drug Side Effects
• 16.2 Incidence And Prevalence of Clinical Indications

17 Asia-Pacific Market

• 17.1 Summary
• 17.2 Market Overview
  • 17.2.1 Region Information
  • 17.2.2 Market Information
  • 17.2.3 Background Information
  • 17.2.4 Government Initiatives
  • 17.2.5 Regulations
  • 17.2.6 Regulatory Bodies
  • 17.2.7 Major Associations
  • 17.2.8 Taxes Levied
  • 17.2.9 Corporate Tax Structure
  • 17.2.10 Investments
  • 17.2.11 Major Companies
• 17.3 Asia-Pacific Respiratory Syncytial Virus Vaccine Market, Segmentation By Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 17.4 Asia-Pacific Respiratory Syncytial Virus Vaccine Market, Segmentation By Clinical Indications, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 17.5 Asia-Pacific Respiratory Syncytial Virus Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 17.6 Asia-Pacific Respiratory Syncytial Virus Vaccine Market: Country Analysis
• 17.7 China Market
• 17.8 Summary
• 17.9 Market Overview
  • 17.9.1 Country Information
  • 17.9.2 Market Information
  • 17.9.3 Background Information
  • 17.9.4 Government Initiatives
  • 17.9.5 Regulations
  • 17.9.6 Regulatory Bodies
  • 17.9.7 Major Associations
  • 17.9.8 Taxes Levied
  • 17.9.9 Corporate Tax Structure
  • 17.9.10 Investments
  • 17.9.11 Major Companies
• 17.10 China Respiratory Syncytial Virus Vaccine Market, Segmentation By Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 17.11 China Respiratory Syncytial Virus Vaccine Market, Segmentation By Clinical Indications, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 17.12 China Respiratory Syncytial Virus Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 17.13 India Market
• 17.14 India Respiratory Syncytial Virus Vaccine Market, Segmentation By Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 17.15 India Respiratory Syncytial Virus Vaccine Market, Segmentation By Clinical Indications, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 17.16 India Respiratory Syncytial Virus Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 17.17 Japan Market
• 17.18 Summary
• 17.19 Market Overview
  • 17.19.1 Country Information
  • 17.19.2 Market Information
  • 17.19.3 Background Information
  • 17.19.4 Government Initiatives
  • 17.19.5 Regulations
  • 17.19.6 Regulatory Bodies
  • 17.19.7 Major Associations
  • 17.19.8 Taxes Levied
  • 17.19.9 Corporate Tax Structure
  • 17.19.10 Investments
  • 17.19.11 Major Companies
• 17.20 Japan Respiratory Syncytial Virus Vaccine Market, Segmentation By Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 17.21 Japan Respiratory Syncytial Virus Vaccine Market, Segmentation By Clinical Indications, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 17.22 Japan Respiratory Syncytial Virus Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 17.23 South Korea Market
• 17.24 Summary
• 17.25 Market Overview
  • 17.25.1 Country Information
  • 17.25.2 Market Information
  • 17.25.3 Background Information
  • 17.25.4 Government Initiatives
  • 17.25.5 Regulations
  • 17.25.6 Regulatory Bodies
  • 17.25.7 Major Associations
  • 17.25.8 Taxes Levied
  • 17.25.9 Corporate Tax Structure
  • 17.25.10 Investments
  • 17.25.11 Major Companies
• 17.26 South Korea Respiratory Syncytial Virus Vaccine Market, Segmentation By Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 17.27 South Korea Respiratory Syncytial Virus Vaccine Market, Segmentation By Clinical Indications, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 17.28 South Korea Respiratory Syncytial Virus Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 17.29 Australia Market
• 17.30 Australia Respiratory Syncytial Virus Vaccine Market, Segmentation By Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 17.31 Australia Respiratory Syncytial Virus Vaccine Market, Segmentation By Clinical Indications, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 17.32 Australia Respiratory Syncytial Virus Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)

18 Western Europe Market

• 18.1 Summary
• 18.2 Market Overview
  • 18.2.1 Region Information
  • 18.2.2 Market Information
  • 18.2.3 Background Information
  • 18.2.4 Government Initiatives
  • 18.2.5 Regulations
  • 18.2.6 Regulatory Bodies
  • 18.2.7 Major Associations
  • 18.2.8 Taxes Levied
  • 18.2.9 Corporate Tax Structure
  • 18.2.10 Investments
  • 18.2.11 Major Companies
• 18.3 Western Europe Respiratory Syncytial Virus Vaccine Market, Segmentation By Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 18.4 Western Europe Respiratory Syncytial Virus Vaccine Market, Segmentation By Clinical Indications, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 18.5 Western Europe Respiratory Syncytial Virus Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 18.6 Western Europe Respiratory Syncytial Virus Vaccine Market: Country Analysis
• 18.7 UK Market
• 18.8 UK Respiratory Syncytial Virus Vaccine Market, Segmentation By Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 18.9 UK Respiratory Syncytial Virus Vaccine Market, Segmentation By Clinical Indications, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 18.10 UK Respiratory Syncytial Virus Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 18.11 Germany Market
• 18.12 Germany Respiratory Syncytial Virus Vaccine Market, Segmentation By Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 18.13 Germany Respiratory Syncytial Virus Vaccine Market, Segmentation By Clinical Indications, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 18.14 Germany Respiratory Syncytial Virus Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 18.15 France Market
• 18.16 France Respiratory Syncytial Virus Vaccine Market, Segmentation By Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 18.17 France Respiratory Syncytial Virus Vaccine Market, Segmentation By Clinical Indications, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 18.18 France Respiratory Syncytial Virus Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)

19 Eastern Europe Market

• 19.1 Summary
• 19.2 Market Overview
  • 19.2.1 Region Information
  • 19.2.2 Market Information
  • 19.2.3 Background Information
  • 19.2.4 Government Initiatives
  • 19.2.5 Regulations
  • 19.2.6 Regulatory Bodies
  • 19.2.7 Major Associations
  • 19.2.8 Taxes Levied
  • 19.2.9 Corporate Tax Structure
  • 19.2.10 Major Companies
• 19.3 Eastern Europe Respiratory Syncytial Virus Vaccine Market, Segmentation By Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 19.4 Eastern Europe Respiratory Syncytial Virus Vaccine Market, Segmentation By Clinical Indications, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 19.5 Eastern Europe Respiratory Syncytial Virus Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)

20 North America Market

• 20.1 Summary
• 20.2 Market Overview
  • 20.2.1 Region Information
  • 20.2.2 Market Information
  • 20.2.3 Background Information
  • 20.2.4 Government Initiatives
  • 20.2.5 Regulations
  • 20.2.6 Regulatory Bodies
  • 20.2.7 Major Associations
  • 20.2.8 Taxes Levied
  • 20.2.9 Corporate Tax Structure
  • 20.2.10 Investments
  • 20.2.11 Major Companies
• 20.3 North America Respiratory Syncytial Virus Vaccine Market, Segmentation By Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 20.4 North America Respiratory Syncytial Virus Vaccine Market, Segmentation By Clinical Indications, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 20.5 North America Respiratory Syncytial Virus Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 20.6 North America Respiratory Syncytial Virus Vaccine Market: Country Analysis
• 20.7 USA Market
• 20.8 Summary
• 20.9 Market Overview
  • 20.9.1 Country Information
  • 20.9.2 Market Information
  • 20.9.3 Background Information
  • 20.9.4 Government Initiatives
  • 20.9.5 Regulations
  • 20.9.6 Regulatory Bodies
  • 20.9.7 Major Associations
  • 20.9.8 Taxes Levied
  • 20.9.9 Corporate Tax Structure
  • 20.9.10 Investments
  • 20.9.11 Major Companies
• 20.10 USA Respiratory Syncytial Virus Vaccine Market, Segmentation By Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 20.11 USA Respiratory Syncytial Virus Vaccine Market, Segmentation By Clinical Indications, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 20.12 USA Respiratory Syncytial Virus Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 20.13 Canada Market
• 20.14 Summary
• 20.15 Market Overview
  • 20.15.1 Country Information
  • 20.15.2 Market Information
  • 20.15.3 Background Information
  • 20.15.4 Government Initiatives
  • 20.15.5 Regulations
  • 20.15.6 Regulatory Bodies
  • 20.15.7 Major Associations
  • 20.15.8 Taxes Levied
  • 20.15.9 Corporate Tax Structure
  • 20.15.10 Investments
  • 20.15.11 Major Companies
• 20.16 Canada Respiratory Syncytial Virus Vaccine Market, Segmentation By Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 20.17 Canada Respiratory Syncytial Virus Vaccine Market, Segmentation By Clinical Indications, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 20.18 Canada Respiratory Syncytial Virus Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)

21 South America Market

• 21.1 Summary
• 21.2 Market Overview
  • 21.2.1 Region Information
  • 21.2.2 Market Information
  • 21.2.3 Background Information
  • 21.2.4 Government Initiatives
  • 21.2.5 Regulations
  • 21.2.6 Regulatory Bodies
  • 21.2.7 Major Associations
  • 21.2.8 Taxes Levied
  • 21.2.9 Corporate Tax Structure
  • 21.2.10 Major Companies
• 21.3 South America Respiratory Syncytial Virus Vaccine Market, Segmentation By Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 21.4 South America Respiratory Syncytial Virus Vaccine Market, Segmentation By Clinical Indications, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 21.5 South America Respiratory Syncytial Virus Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)

22 Middle East Market

• 22.1 Summary
• 22.2 Market Overview
  • 22.2.1 Region Information
  • 22.2.2 Market Information
  • 22.2.3 Background Information
  • 22.2.4 Government Initiatives
  • 22.2.5 Regulations
  • 22.2.6 Regulatory Bodies
  • 22.2.7 Major Associations
  • 22.2.8 Taxes Levied
  • 22.2.9 Corporate Tax Structure
  • 22.2.10 Major Companies
• 22.3 Middle East Respiratory Syncytial Virus Vaccine Market, Segmentation By Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 22.4 Middle East Respiratory Syncytial Virus Vaccine Market, Segmentation By Clinical Indications, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 22.5 Middle East Respiratory Syncytial Virus Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)

23 Africa Market

• 23.1 Summary
• 23.2 Market Overview
  • 23.2.1 Region Information
  • 23.2.2 Market Information
  • 23.2.3 Background Information
  • 23.2.4 Government Initiatives
  • 23.2.5 Regulations
  • 23.2.6 Regulatory Bodies
  • 23.2.7 Major Associations
  • 23.2.8 Taxes Levied
  • 23.2.9 Corporate Tax Structure
  • 23.2.10 Major Companies
• 23.3 Africa Respiratory Syncytial Virus Vaccine Market, Segmentation By Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 23.4 Africa Respiratory Syncytial Virus Vaccine Market, Segmentation By Clinical Indications, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 23.5 Africa Respiratory Syncytial Virus Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)

24 Competitive Landscape And Company Profiles

• 24.1 Company Profiles
• 24.2 GlaxoSmithKline plc
  • 24.2.1 Company Overview
  • 24.2.2 Products And Services
  • 24.2.3 Business Strategy
  • 24.2.4 Financial Overview
• 24.3 Pfizer Inc.
  • 24.3.1 Company Overview
  • 24.3.2 Products And Services
  • 24.3.3 Business Strategy
  • 24.3.4 Financial Overview
• 24.4 Moderna Inc.
  • 24.4.1 Company Overview
  • 24.4.2 Products And Services
  • 24.4.3 Business Strategy
  • 24.4.4 Financial Overview
• 24.5 Janssen (J&J)
  • 24.5.1 Company Overview
  • 24.5.2 Products And Services
  • 24.5.3 Financial Overview
• 24.6 Bavarian Nordic A/S
  • 24.6.1 Company Overview
  • 24.6.2 Products And Services
  • 24.6.3 Financial Overview

25 Other Major And Innovative Companies

• 25.1 AstraZeneca (Icosavax asset)
  • 25.1.1 Company Overview
  • 25.1.2 Products And Services
• 25.2 Novavax
  • 25.2.1 Company Overview
  • 25.2.2 Products And Services
• 25.3 Clover Biopharmaceuticals
  • 25.3.1 Company Overview
  • 25.3.2 Products And Services
• 25.4 Codagenix
  • 25.4.1 Company Overview
  • 25.4.2 Products And Services
• 25.5 Meissa Vaccines
  • 25.5.1 Company Overview
  • 25.5.2 Products And Services
• 25.6 VaxArt
  • 25.6.1 Company Overview
  • 25.6.2 Products And Services
• 25.7 VBI Vaccines
  • 25.7.1 Company Overview
  • 25.7.2 Products And Services
• 25.8 Vicebio
  • 25.8.1 Company Overview
  • 25.8.2 Products And Services
• 25.9 BlueWillow Biologics
  • 25.9.1 Company Overview
  • 25.9.2 Products And Services
• 25.10 Blue Lake Biotechnology
  • 25.10.1 Company Overview
  • 25.10.2 Products And Services
• 25.11 Virometix AG
  • 25.11.1 Company Overview
  • 25.11.2 Products And Services
• 25.12 MAXVAX Biotechnology Limited
  • 25.12.1 Company Overview
  • 25.12.2 Products And Services
• 25.13 ADMA Biologics
  • 25.13.1 Company Overview
  • 25.13.2 Products And Services
• 25.14 Advaccine Biopharmaceuticals
  • 25.14.1 Company Overview
  • 25.14.2 Products And Services
• 25.15 Daiichi Sankyo
  • 25.15.1 Company Overview
  • 25.15.2 Products And Services

26 Global Respiratory Syncytial Virus Vaccine Market Pipeline Analysis

• 26.1 High Level Clinic Trail Information

27 Competitive Benchmarking

28 Competitive Dashboard

29 Key Mergers And Acquisitions

• 29.1 Sanofi Acquired Vicebio
• 29.2 AstraZeneca Acquired Icosavax

30 Recent Developments In Respiratory Syncytial Virus Vaccine

• 30.1 FDA approves Enflonsia (clesrovimab-cfor) for infant RSV prevention

31 Opportunities And Strategies

• 31.1 Global Respiratory Syncytial Virus Vaccine Market In 2030 - Countries Offering Most New Opportunities
• 31.2 Global Respiratory Syncytial Virus Vaccine Market In 2030 - Segments Offering Most New Opportunities
• 31.3 Global Respiratory Syncytial Virus Vaccine Market In 2030 - Growth Strategies
  • 31.3.1 Market Trend Based Strategies
  • 31.3.2 Competitor Strategies

32 Respiratory Syncytial Virus Vaccine Market, Conclusions And Recommendations

• 32.1 Conclusions
• 32.2 Recommendations
  • 32.2.1 Product
  • 32.2.2 Place
  • 32.2.3 Price
  • 32.2.4 Promotion
  • 32.2.5 People

33 Appendix

• 33.1 Geographies Covered
• 33.2 Market Data Sources
• 33.3 Research Methodology
• 33.4 Currencies
• 33.5 The Business Research Company
• 33.6 Copyright and Disclaimer